SmithKline OTC switch strategy starting at Phase III after U.K. Tagamet switch failures.
This article was originally published in The Tan Sheet
Executive Summary
SMITHKLINE BEECHAM OTC SWITCH STRATEGIES STARTING IN PHASE III of Rx development: an internal switch team is beginning to formulate OTC strategies while medicines are still in their pre-approval clinical trials, SmithKline Beecham Switches Marketing Manager Mandy Johnson said at a conference on the European OTC marketplace in Amsterdam Sept. 29.